Literature DB >> 31482124

Enhancement of the Anti-Aggregation Activity of a Molecular Chaperone Using a Rationally Designed Post-Translational Modification.

Philip R Lindstedt1, Francesco A Aprile1, Maria J Matos1, Michele Perni1, Jean B Bertoldo1, Barbara Bernardim1, Quentin Peter1, Gonzalo Jiménez-Osés2,3, Tuomas P J Knowles1, Christopher M Dobson1, Francisco Corzana2, Michele Vendruscolo1, Gonçalo J L Bernardes1,4.   

Abstract

Protein behavior is closely regulated by a plethora of post-translational modifications (PTMs). It is therefore desirable to develop approaches to design rational PTMs to modulate specific protein functions. Here, we report one such method, and we illustrate its successful implementation by potentiating the anti-aggregation activity of a molecular chaperone. Molecular chaperones are a multifaceted class of proteins essential to protein homeostasis, and one of their major functions is to combat protein misfolding and aggregation, a phenomenon linked to a number of human disorders. In this work, we conjugated a small-molecule inhibitor of the aggregation of α-synuclein, a process associated with Parkinson's disease (PD), to a specific cysteine residue on human Hsp70, a molecular chaperone with five free cysteines. We show that this regioselective conjugation augments in vitro the anti-aggregation activity of Hsp70 in a synergistic manner. This Hsp70 variant also displays in vivo an enhanced suppression of α-synuclein aggregation and its associated toxicity in a Caenorhabditis elegans model of PD.

Entities:  

Year:  2019        PMID: 31482124      PMCID: PMC6716132          DOI: 10.1021/acscentsci.9b00467

Source DB:  PubMed          Journal:  ACS Cent Sci        ISSN: 2374-7943            Impact factor:   14.553


  43 in total

1.  PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations.

Authors:  Todd J Dolinsky; Jens E Nielsen; J Andrew McCammon; Nathan A Baker
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

2.  Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice.

Authors:  C J Cummings; Y Sun; P Opal; B Antalffy; R Mestril; H T Orr; W H Dillmann; H Y Zoghbi
Journal:  Hum Mol Genet       Date:  2001-07-01       Impact factor: 6.150

Review 3.  Molecular chaperones and protein quality control.

Authors:  Bernd Bukau; Jonathan Weissman; Arthur Horwich
Journal:  Cell       Date:  2006-05-05       Impact factor: 41.582

Review 4.  Modulation of neurodegeneration by molecular chaperones.

Authors:  Paul J Muchowski; Jennifer L Wacker
Journal:  Nat Rev Neurosci       Date:  2005-01       Impact factor: 34.870

5.  Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.

Authors:  Pavan K Auluck; H Y Edwin Chan; John Q Trojanowski; Virginia M Y Lee; Nancy M Bonini
Journal:  Science       Date:  2001-12-20       Impact factor: 47.728

6.  Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species.

Authors:  Matthew M Dedmon; John Christodoulou; Mark R Wilson; Christopher M Dobson
Journal:  J Biol Chem       Date:  2005-01-25       Impact factor: 5.157

7.  Alpha-synuclein and chaperones in dementia with Lewy bodies.

Authors:  Ippolita Cantuti-Castelvetri; Jochen Klucken; Martin Ingelsson; Karunya Ramasamy; Pamela J McLean; Matthew P Frosch; Bradley T Hyman; David G Standaert
Journal:  J Neuropathol Exp Neurol       Date:  2005-12       Impact factor: 3.685

8.  Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation.

Authors:  Jason E Gestwicki; Gerald R Crabtree; Isabella A Graef
Journal:  Science       Date:  2004-10-29       Impact factor: 47.728

Review 9.  Hsp70 chaperones: cellular functions and molecular mechanism.

Authors:  M P Mayer; B Bukau
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

10.  Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity.

Authors:  Jochen Klucken; Youngah Shin; Eliezer Masliah; Bradley T Hyman; Pamela J McLean
Journal:  J Biol Chem       Date:  2004-03-25       Impact factor: 5.157

View more
  5 in total

Review 1.  Combating deleterious phase transitions in neurodegenerative disease.

Authors:  April L Darling; James Shorter
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-02-05       Impact factor: 4.739

2.  Disease-associated mutations within the yeast DNAJB6 homolog Sis1 slow conformer-specific substrate processing and can be corrected by the modulation of nucleotide exchange factors.

Authors:  Ankan K Bhadra; Michael J Rau; Jil A Daw; James A J Fitzpatrick; Conrad C Weihl; Heather L True
Journal:  Nat Commun       Date:  2022-08-05       Impact factor: 17.694

Review 3.  Do Post-Translational Modifications Influence Protein Aggregation in Neurodegenerative Diseases: A Systematic Review.

Authors:  Larissa-Nele Schaffert; Wayne G Carter
Journal:  Brain Sci       Date:  2020-04-11

4.  Unveiling Druggable Pockets by Site-Specific Protein Modification: Beyond Antibody-Drug Conjugates.

Authors:  Dailén G Martínez; Stefan Hüttelmaier; Jean B Bertoldo
Journal:  Front Chem       Date:  2020-10-21       Impact factor: 5.221

5.  Dichloro Butenediamides as Irreversible Site-Selective Protein Conjugation Reagent.

Authors:  Victor Laserna; Daniel Abegg; Cláudia F Afonso; Esther M Martin; Alexander Adibekian; Peter Ravn; Francisco Corzana; Gonçalo J L Bernardes
Journal:  Angew Chem Int Ed Engl       Date:  2021-09-29       Impact factor: 15.336

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.